Haemonetics (NYSE: HAE) retires $300M zero-coupon 2026 convertible notes in cash

Rhea-AI Filing Summary

Haemonetics Corporation has repaid in full its 0.00% Convertible Senior Notes due 2026 at their scheduled maturity. The company paid an aggregate of $300,000,000 in cash, equal to the outstanding principal on the notes, using a combination of cash on hand and borrowings under its revolving credit facility.

No noteholders chose to convert their notes into equity before the cut-off date, so the entire principal was settled in cash rather than shares. The capped call transactions that were entered into when the notes were originally issued have now expired in line with their terms as the notes reached maturity.

Insights

Capital structure analyst

Haemonetics settled a $300M convertible maturity entirely in cash.

Haemonetics Corporation repaid its 0.00% Convertible Senior Notes due 2026 at maturity, using $300,000,000 in cash, funded by cash on hand and draws under its revolving credit facility. No holders converted, so there was no equity issuance tied to this maturity.

This replaces a zero‑coupon convertible instrument with increased usage of the revolving credit line, shifting the mix of obligations without adding new dilution from these notes. Future filings may clarify any changes in interest expense or remaining revolver capacity following this repayment.

0000313143false00003131432026-03-032026-03-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 3, 2026

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts

001-14041

04-2882273

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

125 Summer Street

Boston, MA 02110

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $.01 par value per share			HAE			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 2, 2026, Haemonetics Corporation (the “Company”) repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026 (the “Notes”). The Company paid an aggregate amount of $300,000,000 in cash, representing the outstanding principal amount of the Notes. The repayment was funded with cash on hand and borrowings under the Company’s revolving credit facility. No holders exercised conversion rights with respect to the Notes prior to the close of business on the second scheduled trading day immediately preceding the maturity date. The capped call transactions entered into in connection with the issuance of the Notes expired in accordance with their terms upon the maturity of the Notes.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

March 3, 2026

By:

/s/ James C. D’Arecca

Name:

James C. D’Arecca

Title:

Executive Vice President, Chief Financial Officer

FAQ

What did Haemonetics Corporation (HAE) announce in this Form 8-K?

Haemonetics announced it repaid in full its 0.00% Convertible Senior Notes due 2026. The company paid the entire principal of $300,000,000 in cash at maturity, funded with cash on hand and borrowings under its revolving credit facility.

How much principal did Haemonetics (HAE) repay on its 2026 convertible notes?

Haemonetics repaid an aggregate principal amount of $300,000,000 on its 0.00% Convertible Senior Notes due 2026. This cash payment satisfied the full outstanding principal balance of the notes at maturity in accordance with the original terms.

Did Haemonetics (HAE) noteholders convert their 2026 convertible notes into stock?

No, noteholders did not exercise conversion rights on the 0.00% Convertible Senior Notes due 2026. The filing states that no holders converted prior to the specified cut-off date, so the full $300,000,000 principal was repaid entirely in cash instead of shares.

How did Haemonetics fund the repayment of its $300 million 2026 notes?

Haemonetics funded the $300,000,000 repayment with a mix of cash on hand and borrowings under its revolving credit facility. This approach allowed the company to retire the maturing convertible notes without issuing equity tied to these instruments.

What happened to the capped call transactions related to Haemonetics’ 2026 notes?

The capped call transactions associated with the 0.00% Convertible Senior Notes due 2026 expired when the notes matured. The filing explains that these derivative arrangements terminated in accordance with their terms upon maturity of the underlying notes.

Does the Haemonetics (HAE) 8-K indicate any change in liability treatment?

The 8-K indicates that the 0.00% Convertible Senior Notes due 2026 have been fully repaid at maturity. As a result, this specific $300,000,000 convertible debt obligation has been settled, with repayment funded through cash resources and revolving credit facility borrowings.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.3 KB